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Positive family anamnesis is an important risk factor for cancer, and therefore further investigations need to be done if familial
aggregation of cancer is observed. Due to a rare combination of urinary tract and bone tumors occurring in the family presented
herein we hypothesized a hereditary predisposition and thus, Li-Fraumeni syndrome was considered to be the most likely
diﬀerential diagnosis. To conﬁrm Li-Fraumeni syndrome, we set out to investigate this case by analyzing the tumor suppressor
gene p53. However, taking into account all the diagnostic results obtained, Li-Fraumeni syndrome could not be conﬁrmed, but
there is still uncertainty regarding a deﬁnitive diagnosis.
1.Introduction
Positive family anamnesis is an important risk factor for
cancer, and therefore further investigations need to be done
if a familial aggregation of cancer is observed. Due to a
rare combination of primary tumors occurring in the family
presented herein [1], weassumedahereditary predisposition
and thus, Li-Fraumeni syndrome (LFS) was considered to be
the most likely diﬀerential diagnosis. First reported by Li and
Fraumeni in 1969 [2], this syndrome is characterized by its
onset at an early age and an autosomal dominant mode of
inheritancewithgermlinemutationsatthetumorsuppressor
gene p53 [3].
To conﬁrm the hypothesized diagnosis of LFS, we set out
to investigate this case by analyzing the tumor suppressor
gene p53.
2. Case Presentation
A 76-year-old Caucasian female was referred to our depart-
ment due to a 6-month history of constant aching pain
over her left hip region. Imaging features were very typical
of a primary bone tumor and thus, as tentative diagno-
sis chondrosarcoma was made by the reporting radiologist
(Figure 1). Subsequently performed tumor staging revealed
the tumor as being a primary with an otherwise clear bone
scan, CT chest, and abdomen. There was no evidence of
metastatic disease. However, imaging of the kidneys suggest-
ed possible renal cell carcinoma involving the right kidney.
Biopsy specimen of the proximal left femur revealed
a biphasic tumor composed of a cartilaginous component
with abrupt transition into a noncartilaginous malignant
mesenchymal component (Figure 2). The diagnosis of a
dediﬀerentiated chondrosarcoma was made. The dediﬀeren-
tiated part was consistent with an osteosarcoma.
The patient underwent limb salvage surgery, performed
according to standardized local protocol by surgeons spe-
cialized in oncologic surgery, followed by endoprosthetic
replacement.Widesurgicalmarginswereachieved.Although
the patient was reasonably ﬁt, adjuvant chemotherapy was
not given due to the patient’s age.
During the further course of treatment, the suspicious
condition in the right kidney, that had already been present
during initial tumor staging prior to limb salvage surgery,
was diagnosed as clear-cell renal cell carcinoma (Figure 2)
and immediately subjected to nephrectomy. There was no
evidence of metastatic disease. After more than 5 years of
followup the patient is still free of disease.2 Case Reports in Medicine
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Figure 1: Preoperative MRI showing the left femur of a 76-year-old Caucasian female with diagnosis dediﬀerentiated chondrosarcoma (a)
anterior-posterior axial view, (b) anterior-posterior front view.
(a) (b)
Figure 2: (a) Biopsy specimen of the proximal left femur of a 76-year-old Caucasian female with diagnosis dediﬀerentiated chondrosarcoma
(400x), H.E. (b) same patient, clear-cell renal cell carcinoma of the right kidney (400x), H.E.
Besides the current complaints described above, the
patient underwent hysterectomy and cholecystectomy years
ago. She could not remember the reason and there is
no documentation discussing why those operations were
performed. However, her medical family history (Figure 3)
revealed that her youngest brother started suﬀering from
invasive medium- to-low diﬀerentiated urothelial carcinoma
(Figure 4)ofthebladderwhenhewas67-year-old.Hediedat
age 69 of a ﬁbroblastic osteosarcoma (Figure 4) located in his
left femur. Their mother presented with renal cell carcinoma
as well when she was 65-year-old (specimen not available).
To assess the hypothesized diagnosis of LFS, DNA was
isolated from blood samples of the female index patient, and
we analyzed the tumor suppressor gene p53 using semiquan-
titative, multiplex ligation-dependent probe ampliﬁcation
(MLPA, MRC-Holland) to rule out alterations of the TP53
gene. Moreover, the entire coding (exons 2–11) region and
ﬂanking intron regions of TP53 were sequenced. Since both
MLPA and sequenciation did not reveal pathologic changes
of the TP53 gene, the GAG-banding pattern derived from
cell division was analyzed as well. However, chromosomal
aberrations were not detected in the cytogenetic analysis
neither for structural or numerical reasons. Taking into
account all the results obtained, the diagnosis of LFS could
not be conﬁrmed, but there is still uncertainty regarding
a deﬁnitive diagnosis in terms of a possible new genetic
syndrome.
3. Discussion
Due to a rare combination of urinary tract and bone tumors
occurring in the family presented herein, we hypothesizedCase Reports in Medicine 3
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Figure 3: Pedigree of the family presented, RCC: renal cell carcinoma, CHS: chondrosarcoma, OS: osteosarcoma, BL: urothelial carcinoma
of the bladder.
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Figure 4: (a) Biopsy specimen of the proximal left femur of a 69-year-old Caucasian male with diagnosis ﬁbroblastic osteosarcoma (200x),
H.E. (b) same patient, invasive medium- to-low diﬀerentiated urothelial carcinoma of the bladder (400x), H.E.4 Case Reports in Medicine
a hereditary predisposition and thus, the tentative diagnosis
Li-Fraumeni syndrome was made.
In fact, positive family anamnesis is an important risk
factor for cancer. The genetic defect in LFS is a germline
mutation at the tumor suppressor gene p53 with an autoso-
mal dominant mode of inheritance. Accordingly, children of
aﬀected parents are at 50% risk of being mutation carriers.
As the family pedigree shown in Figure 3 points out that
there are a lot of children, a diagnosed syndrome could
be very helpful to reduce risk for unaﬀected oﬀspring.
However, none of the oﬀspring has yet developed cancer
(Figure 3).
Due to a variety of neoplasms and the family history
reported herein, LFS was strongly considered nevertheless.
In contrast to other syndromes, for instance neuroﬁbro-
matosis,tuberoussclerosis,orvonHippel-Lindausyndrome,
LFS is characterized by various but characteristic multiple
primary tumors [1]. Accordingly, signiﬁcant diﬀerences in
the distribution of bone tumors, soft tissue sarcomas, breast
cancer, leukemia, melanoma, lung cancer, tumors of the
gastrointestinal tract and the pancreas should be expected
compared with the general population. Although an early
age at onset is frequent, patients are also at increased risk
of developing multiple primary late-onset malignancies [4].
The overall lifetime risk of cancer is estimated close to
80% in patients with pathologic changes of the TP53 gene;
approximately 40% develops cancer during the ﬁrst two
decades of life [5, 6].
Further explanations like variable expressivity and
germline mosaicism or de novo mutation in the patient
brother’s TP53 gene were considered but ﬁnally denied
due to low probability. Nonmedical explanations, including
alternate paternity or maternity or undisclosed adoption,
wereexploredandruledoutbymeansoffamilyexamination.
Furthermore, a nonsyndromic cause of familial cancer is
still being reasonable as pathologic changes of the TP53
gene have not been proven. Based on current data, some
minor changes found in the DNA sequence can be classiﬁed
as polymorphism without pathologic signiﬁcance; however,
current data may be subject to change. A genetic predis-
position, perhaps due to other, currently unknown factors
may still not be excluded. Besides, MLPA and sequenciation
as methods for genetic testing may perhaps be too lim-
ited. However, these tools are standard procedures in our
institutes.
As the case reported herein implies that families with
highly suspicious medical family history should be closely
monitored to minimize disease-related morbidity. Clinicians
should therefore be aware of genetic syndromes as diﬀer-
ential diagnosis. Further, similar, familial cases should be
reported to address the question of a possible new genetic
syndrome.
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